Royal Bank of Canada
PMVP icon

Royal Bank of Canada’s PMV Pharmaceuticals PMVP Stock Holding History

Royal Bank of Canada’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Buy
904
+832
+1,156% +$1.06K ﹤0.01% 6928
2025
Q4 		$0 Sell
72
-3,983
-98% -$5.33K ﹤0.01% 7518
2025
Q3 		$6K Buy
4,055
+3,605
+801% +$4.99K ﹤0.01% 6661
2025
Q2 		$0 Buy
450
+66
+17% +$65 ﹤0.01% 7266
2025
Q1 		$0 Sell
384
-40,000
-99% -$54.3K ﹤0.01% 7147
2024
Q4 		$61K Buy
40,384
+40,336
+84,033% +$63.9K ﹤0.01% 5594
2024
Q3 		$0 Sell
48
-2,358
-98% -$3.64K ﹤0.01% 7294
2024
Q2 		$4K Buy
2,406
+1,458
+154% +$2.63K ﹤0.01% 6608
2024
Q1 		$2K Sell
948
-11,017
-92% -$20.6K ﹤0.01% 6692
2023
Q4 		$38K Buy
11,965
+5,479
+84% +$14.5K ﹤0.01% 6107
2023
Q3 		$40K Buy
6,486
+2,462
+61% +$16.9K ﹤0.01% 5896
2023
Q2 		$25K Buy
4,024
+1,957
+95% +$10.3K ﹤0.01% 6098
2023
Q1 		$10K Sell
2,067
-2,770
-57% -$19.5K ﹤0.01% 6322
2022
Q4 		$42K Buy
4,837
+4,388
+977% +$46.8K ﹤0.01% 5987
2022
Q3 		$5K Buy
449
+242
+117% +$3.5K ﹤0.01% 6742
2022
Q2 		$3K Sell
207
-1,404
-87% -$20.4K ﹤0.01% 6848
2022
Q1 		$34K Sell
1,611
-4,395
-73% -$77.5K ﹤0.01% 6322
2021
Q4 		$139K Buy
6,006
+3,725
+163% +$90K ﹤0.01% 5680
2021
Q3 		$68K Buy
2,281
+453
+25% +$14.5K ﹤0.01% 5975
2021
Q2 		$62K Buy
1,828
+735
+67% +$24.6K ﹤0.01% 5894
2021
Q1 		$36K Buy
1,093
+678
+163% +$26.7K ﹤0.01% 6093
2020
Q4 		$26K Buy
+415
New +$16.3K ﹤0.01% 5941

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Royal Bank of Canada's PMVP Position: Q1 2026 in Review

Royal Bank of Canada increased its PMV Pharmaceuticals (PMVP) stake by 1,156% in Q1 2026, buying an estimated $1.06K and bringing the position to 904 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6928.

Royal Bank of Canada first reported a position in PMVP in Q4 2020 and has held it in 22 quarters since. The position peaked at $139K in Q4 2021. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Royal Bank of Canada held 904 shares of PMV Pharmaceuticals worth $1K as of Q1 2026.
  • Royal Bank of Canada bought 832 PMV Pharmaceuticals shares in Q1 2026, an estimated $1.06K.
  • PMV Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6928 holding.
  • Royal Bank of Canada first reported a position in PMV Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's PMV Pharmaceuticals position peaked at $139K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.